ATE498012T1 - Menschliche gene in verbindung mit krebs, davon kodierte produkte und anwendungen davon - Google Patents

Menschliche gene in verbindung mit krebs, davon kodierte produkte und anwendungen davon

Info

Publication number
ATE498012T1
ATE498012T1 AT03782072T AT03782072T ATE498012T1 AT E498012 T1 ATE498012 T1 AT E498012T1 AT 03782072 T AT03782072 T AT 03782072T AT 03782072 T AT03782072 T AT 03782072T AT E498012 T1 ATE498012 T1 AT E498012T1
Authority
AT
Austria
Prior art keywords
seq
cancer
applications
dna sequences
sequence listings
Prior art date
Application number
AT03782072T
Other languages
English (en)
Inventor
Rouli Zhou
Genze Shao
Xinrong Liu
Qingyun Zhang
Jingan Rui
Ye Zhang
Yueying Jin
Ming Lin
Sha Zhang
Original Assignee
Univ Beijing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN 02158110 external-priority patent/CN1239700C/zh
Priority claimed from CNB031097863A external-priority patent/CN1328377C/zh
Application filed by Univ Beijing filed Critical Univ Beijing
Application granted granted Critical
Publication of ATE498012T1 publication Critical patent/ATE498012T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03782072T 2002-12-24 2003-12-24 Menschliche gene in verbindung mit krebs, davon kodierte produkte und anwendungen davon ATE498012T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN 02158110 CN1239700C (zh) 2002-12-24 2002-12-24 一个人肝癌相关基因及其编码产物与应用
CNB031097863A CN1328377C (zh) 2003-04-21 2003-04-21 人肝癌相关基因laptm4b的一个等位基因及其编码产物与应用
PCT/CN2003/001109 WO2004058971A1 (en) 2002-12-24 2003-12-24 Human cancer-relating genes, the products encoded thereby and applications thereof

Publications (1)

Publication Number Publication Date
ATE498012T1 true ATE498012T1 (de) 2011-02-15

Family

ID=32683267

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03782072T ATE498012T1 (de) 2002-12-24 2003-12-24 Menschliche gene in verbindung mit krebs, davon kodierte produkte und anwendungen davon

Country Status (7)

Country Link
US (3) US7910711B2 (de)
EP (2) EP1577390B9 (de)
JP (1) JP4617257B2 (de)
AT (1) ATE498012T1 (de)
AU (1) AU2003292867A1 (de)
DE (1) DE60336015D1 (de)
WO (1) WO2004058971A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE498012T1 (de) 2002-12-24 2011-02-15 Univ Beijing Menschliche gene in verbindung mit krebs, davon kodierte produkte und anwendungen davon
US8152628B2 (en) * 2005-08-01 2012-04-10 Igt Methods and devices for authentication and licensing in a gaming network
US8679598B2 (en) 2010-10-08 2014-03-25 Guardian Industries Corp. Vacuum insulated glass (VIG) unit including nano-composite pillars, and/or methods of making the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3091870B2 (ja) * 1989-12-19 2000-09-25 アメリカ合衆国 肝細胞の癌の癌遺伝子
US6878806B2 (en) * 1997-03-14 2005-04-12 Human Genome Sciences, Inc. Human secreted protein HTEEB42
AU4799499A (en) 1998-07-24 2000-02-14 Protegene Inc. Human proteins having hydrophobic domains and dnas encoding these proteins
AU4021700A (en) * 1999-03-22 2000-10-09 Board Of Regents, The University Of Texas System Methods of use of beta1-integrin inhibitors
CA2382015A1 (en) 1999-08-17 2001-02-22 Incyte Genomics, Inc. Membrane associated proteins
EP1242443A4 (de) * 1999-12-23 2005-06-22 Nuvelo Inc Neue nukleinsäuren und polypeptide
US6465620B1 (en) * 2000-01-21 2002-10-15 Hyseq, Inc. Methods and materials relating to novel von Willebrand/Thrombospondin-like polypeptides and polynucleotides
AU2002246502A1 (en) 2000-11-17 2002-08-06 Hyseq, Inc. Nucleic acids and polypeptides
AU2002258518A1 (en) * 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US20050259483A1 (en) * 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
US20060188889A1 (en) * 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
ATE498012T1 (de) 2002-12-24 2011-02-15 Univ Beijing Menschliche gene in verbindung mit krebs, davon kodierte produkte und anwendungen davon
EP1677733A4 (de) * 2003-10-03 2007-09-19 Bayer Pharmaceuticals Corp Genexpressionsprofile und anwendungsverfahren

Also Published As

Publication number Publication date
EP1577390A4 (de) 2006-05-10
EP2230306B1 (de) 2016-05-04
WO2004058971A1 (en) 2004-07-15
EP1577390B1 (de) 2011-02-09
AU2003292867A1 (en) 2004-07-22
US20120148589A1 (en) 2012-06-14
US9470690B2 (en) 2016-10-18
EP1577390A1 (de) 2005-09-21
DE60336015D1 (de) 2011-03-24
EP1577390B9 (de) 2011-03-30
US7910711B2 (en) 2011-03-22
US20070026395A1 (en) 2007-02-01
JP4617257B2 (ja) 2011-01-19
EP2230306A1 (de) 2010-09-22
JP2006522587A (ja) 2006-10-05
US20160238608A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
ATE528397T1 (de) Bei krebs überexprimiertes gen
DK1536006T3 (da) Cancerantigener og anvendelse deraf
ATE333520T1 (de) Neuartige polynukleotide und polypeptide des ifnalpha-21 gens
PE20021098A1 (es) ANTICUERPOS ESPECIFICOS DE CD44v6
DK1667711T3 (da) Forebyggende cancervaccine baseret på BORIS (Brother of Regulator of Imprinted Sites)-molekyle
WO2005049806A3 (en) Novel nucleic acids and polypeptides
DE60336015D1 (de) Menschliche Gene in Verbindung mit Krebs, davon kodierte Produkte und Anwendungen davon
WO2002095067A3 (en) INTERFERON α-14 POLYMORPHISM
WO2001088148A3 (en) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2001051518A3 (en) Nucleic acids encoding human semaphorin proteins and use thereof
WO2002072831A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002046406A3 (en) Human transporter proteins, nucleic acid molecules encoding them,and uses thereof
WO2002081654A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002053718A3 (en) Isolated human phosphodiesterase proteins, nucleic acid molecules encoding human phosphodiesterase proteins, and uses thereof
WO2002057310A3 (en) Human transporter proteins, nucleic acid molecules encoding them, and uses thereof
WO2002024910A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof
WO2002020757A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002079252A8 (en) Isolated human transporter protein, nucleic acid molecules encoding human transporter protein, and uses thereof
WO2002079227A8 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002083900A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002081657A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002083731A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002079432A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002079225A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
WO2002068648A3 (en) Isolated human ras-like proteins, nucleic acid molecules encoding these humans ras-like proteins, and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties